Menu
Recruiting NCT07736911

Discontinuation One Week Recommendations for GLP-1 Receptor Agonists Prior to Esophagogastroduodenoscopy.

Phase III Interventional GLP-1

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Stop for 1 week, GLP-1 non stop.
Who it may be relevant to
Registry conditions: GLP-1. Basic parameters: 18 years — 90 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Taiwan
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Discontinuation One Week Recommendations for GLP-1 Receptor Agonists Prior to Esophagogastroduodenoscopy: A Randomized Controlled Trial.

Overview

This study aims to evaluate the impact of a one-week discontinuation of long-acting glucagon-like peptide-1 receptor agonists (GLP-1 RAs) prior to Esophagogastroduodenoscopy on gastric preparation quality and the need for repeat esophagogastroduodenoscopy (EGD), in order to determine whether a one-week drug interruption constitutes an appropriate pre-procedural recommendation.

Interventions

  • Drug Stop for 1 week
    Stop for 1 week
  • Drug GLP-1 non stop
    GLP-1 non stop

Primary outcome measures

  • This scoring system is referred to as PEACE (Polprep: Effective Assessment of Cleanliness in Esophagogastroduodenoscopy) [Time frame: "From enrollment to the end of treatment at least 30 days]

Eligibility criteria

Inclusion criteria

  • • Current use of GLP-1 receptor agonists (GLP-1 RAs) or tirzepatide (defined as discontinuation for no more than one week).
  • Continuous GLP-1 RA use for at least 4 weeks, or treatment at a near-maximal maintenance dose.
  • Scheduled to undergo esophagogastroduodenoscopy (EGD) for any indication.
  • Age between 18 and 70 years.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Provision of written informed consent.
  • Outpatient status.
  • If currently receiving medications that stimulate or inhibit gastrointestinal motility, these agents must be discontinued at least 3 days prior to EGD.

Exclusion criteria

  • • Severe comorbid conditions precluding safe EGD (e.g., unstable angina, recent myocardial infarction, heart failure, chronic respiratory disease, or bleeding diathesis).
  • History of prior upper gastrointestinal resection (stomach, intestine, or esophagus).
  • Any other condition deemed inappropriate by the treating physician.
  • Body mass index (BMI) > 40 kg/m².
  • Liver cirrhosis.
  • Parkinson's disease.
  • Dementia.
  • Use of tricyclic antidepressants or opioid medications for more than 3 months.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Double blind
Primary purpose
Other

Study locations

Taiwan · 1 center
  • FJUH — New Taipei City

Identifiers

NCT: NCT07736911 · GLP-1 UGI

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗